Octreotide
Orphan Drug Cold Chain RequiredFDA Approved
Description
Octreotide is a synthetic somatostatin analog that mimics natural somatostatin pharmacologically. It is used to treat symptoms of neuroendocrine tumors and hormone-secreting tumors in multiple endocrine neoplasia syndromes. The drug effectively controls hormone hypersecretion and tumor-related symptoms.
Indications & Therapeutic Use
Acromegaly, carcinoid tumors, VIPomas, gastroenteropancreatic neuroendocrine tumors, multiple endocrine neoplasia
Linked Diseases:
multiple endocrine neoplasia
D44.8D009377
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Octreotide
| Generic Name | Octreotide |
| Brands | 1 brand available |
| Active Ingredient | Octreotide acetate |
| Drug Class | Acromegaly |
| Manufacturer | Novartis |
| Dosage Forms | Subcutaneous/IV injection, 50mcg/mL, 100mcg/mL, 500mcg/mL; IM depot 10mg, 20mg, 30mg |
| Medical Code | H01CB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00004874 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes